Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease worldwide. Although liver biopsy remains the histological reference standard for assessing steatohepatitis, fibrosis stage, and therapeutic response, its invasiveness, sampling variability, and limited suitability for repeated monitoring have driven the development of non-invasive approaches. Clinical scores based on routine variables, omics-derived biomarkers, quantitative imaging techniques, and multimodal integrative models have substantially expanded the landscape of MASLD assessment. This review summarizes current progress in non-invasive evaluation of MASLD from a clinically oriented perspective, covering traditional blood-based and clinical tools, omics approaches, quantitative imaging, and multimodal integration. Particular attention is given to how these tools may serve different clinical purposes, including targeted screening or case-finding, specialist referral, fibrosis stratification, prognostic assessment, longitudinal monitoring, and precision, risk-stratified care. Major translation barriers remain, including the predominance of technology-driven instead of clinically driven study designs, the imperfect nature of biopsy-based reference standards, insufficient head-to-head comparisons across modalities, limited external validation of high-dimensional models, and uncertainty regarding real-world implementation. We argue that the future of non-invasive assessment in MASLD lies not in identifying a universally superior single modality, but in developing a clinical-context-specific, stepwise, and biologically interpretable framework that aligns non-invasive tools with distinct clinical needs and decision points.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: